Jefferies Financial Group Inc. Invests $2.88 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Jefferies Financial Group Inc. acquired 29,530 shares in Lantheus Holdings, valued at approximately $2.88 million, indicating significant institutional interest in the medical equipment provider.
• Lantheus reported $1.53 EPS for the latest quarter, missing analysts' expectations of $1.64, though its revenue increased by 0.8% year-over-year.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Lantheus, with a target price reflecting potential future growth in the company's stock.

Jefferies Financial Group Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 29,530 shares of the medical equipment provider's stock, valued at approximately $2,882,000.

A number of other institutional investors also recently bought and sold shares of LNTH. Norges Bank purchased a new stake in Lantheus during the fourth quarter worth $26,189,000. Pictet Asset Management Holding SA lifted its position in shares of Lantheus by 12.1% in the fourth quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after acquiring an additional 1,113 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Lantheus in the fourth quarter valued at $20,022,000. Massachusetts Financial Services Co. MA lifted its position in shares of Lantheus by 37.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 323,900 shares of the medical equipment provider's stock valued at $28,976,000 after acquiring an additional 87,412 shares in the last quarter. Finally, Foundry Partners LLC lifted its position in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after acquiring an additional 133 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Up 5.3%

Shares of NASDAQ LNTH traded up $2.74 on Thursday, hitting $54.61. The company had a trading volume of 655,286 shares, compared to its average volume of 1,097,705. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The business has a 50 day moving average of $77.09 and a two-hundred day moving average of $87.42. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $3.78 billion, a P/E ratio of 15.62 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.69 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. JMP Securities reduced their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research report on Thursday. B. Riley dropped their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average price target of $114.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.